文献速递药物相互作用药物不良反应与药物警戒

淋巴瘤患者中左乙拉西坦与大剂量甲氨蝶呤无药物相互作用

Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
PubMed 文献 · Pharmacotherapy · 2021-03-16

该回顾性分析纳入430例接受大剂量甲氨蝶呤(HDMTX)治疗的成人淋巴瘤患者,共1993次给药,其中88例(20.5%)同时使用左乙拉西坦。结果显示,合用左乙拉西坦与延迟甲氨蝶呤排泄(OR=0.80,95%CI 0.47-1.34,p=0.39)及急性肾损伤(OR=0.83,95%CI 0.52-1.33,p=0.28)风险增加无关,支持两药可安全联用。

要点

  • 合用左乙拉西坦未增加延迟甲氨蝶呤排泄风险(13.4% vs 16.3%,OR=0.80,p=0.39)。
  • 合用左乙拉西坦未增加急性肾损伤风险(15.6% vs 17.0%,OR=0.83,p=0.28)。
  • 左乙拉西坦与大剂量甲氨蝶呤可安全联用。

核心结论

  • 大剂量甲氨蝶呤与左乙拉西坦联用不增加延迟甲氨蝶呤排泄或急性肾损伤风险,支持两药安全合用。

研究设计与样本

  • 回顾性分析,纳入430例接受HDMTX(4小时输注)的成人淋巴瘤患者,共1993次给药,其中88例(20.5%)同时使用左乙拉西坦。

主要发现

  • 延迟排泄发生率:合用左乙拉西坦组13.4%,未合用组16.3%(OR=0.80,95%CI 0.47-1.34,p=0.39)。
  • 急性肾损伤发生率:合用组15.6%,未合用组17.0%(OR=0.83,95%CI 0.52-1.33,p=0.28)。
  • 中位住院时间:合用组4.2天,未合用组4.1天(p=0.039)。
  • 多变量分析显示,仅年龄、体表面积、系统性DLBCL伴CNS受累诊断、血清肌酐、血红蛋白、总胆红素及HDMTX剂量与延迟排泄相关。

临床怎么用

  • 临床可考虑将左乙拉西坦与HDMTX联用,无需因潜在药物相互作用而避免合用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To determine whether there is a drug-drug interaction precluding the concomitant use of levetiracetam and high-dose methotrexate (HDMTX). DESIGN: Retrospective analysis. SETTING: Large academic tertiary care medical center. PATIENTS: Adult lymphoma patients who received HDMTX as a 4-h infusion with or without concomitant levetiracetam. MEASUREMENTS AND MAIN RESULTS: Generalized estimating equations clustered on patient were used to assess each outcome. The primary outcome was the incidence of delayed MTX elimination (MTX level >1 µmol/L at 48 h). Secondary outcomes included incidence of acute kidney injury (AKI) and hospital length of stay (LOS). The 430 included patients receiving 1993 doses of HDMTX had a median (IQR) age of 66 (57.5, 72.6) years, 88 (20.5%) received concomitant levetiracetam with at least one dose of MTX, 267 (62.1%) were male, and 397 (92.3%) were Caucasian. HDMTX doses ranged from 1 to 8 g/m2 . The most common lymphoma diagnoses were systemic diffuse large B-cell lymphoma (DLBCL; 58.5%) and systemic DLBCL with central nervous system (CNS) involvement (32.8%). Rates of delayed elimination with and without levetiracetam were 13.4% and 16.3%, respectively (OR = 0.80, 95% CI 0.47-1.34, p = 0.39). AKI occurred in 15.6% and 17.0% of patients with and without concomitant levetiracetam, respectively (OR = 0.83, 95% CI 0.52-1.33, p = 0.28). The median LOS with and without levetiracetam was 4.2 and 4.1 days, respectively (p = 0.039). On multivariable analyses, only age, body surface area, diagnosis of systemic DLBCL with CNS involvement, serum creatinine, hemoglobin, total bilirubin, and dose of HDMTX were associated with delayed elimination. CONCLUSIONS: High-dose methotrexate administered with concomitant levetiracetam was not associated with increased risk for delayed MTX elimination or AKI. These results support that levetiracetam and HDMTX are safe for coadministration.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. DeFino CE, Barreto JN, Pawlenty AG, et al. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma. Pharmacotherapy. 2021. PMID: 33655525. doi:10.1002/phar.2516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。